{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T05:39:46Z","timestamp":1792561186569,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12149-025-02086-9","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T19:58:25Z","timestamp":1752609505000},"page":"1278-1286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of diagnostic performance between manual diagnosis following PROMISE V2 and aPROMISE utilizing Ga\/F-PSMA PET\/CT"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1124-2322","authenticated-orcid":false,"given":"Yuki","family":"Enei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuya","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Kuruma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieko","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat P.","family":"Lenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"2086_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","volume":"25","author":"MS Hofman","year":"2024","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, et al. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2024;25:99\u2013107.","journal-title":"Lancet Oncol"},{"key":"2086_CR2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"2086_CR3","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404:1227\u201339.","journal-title":"Lancet"},{"key":"2086_CR4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT. J Nucl Med. 2018;59:469\u201378.","journal-title":"J Nucl Med"},{"key":"2086_CR5","first-page":"2496","volume":"63","author":"J Calais","year":"2022","unstructured":"Calais J, Eiber M, Iagaru A, Anand A, Sjostrand K, Bjartell A, et al. Prospectively planned and independent validation of aPROMISE in a phase III CONDOR study for rapid lesion detection and standardized quantitative evaluation for 18F-DCFPyL (PSMA) imaging in prostate cancer. J Nucl Med. 2022;63:2496.","journal-title":"J Nucl Med"},{"key":"2086_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2967\/jnumed.120.261863","volume":"63","author":"N Nickols","year":"2022","unstructured":"Nickols N, Anand A, Johnsson K, Brynolfsson J, Borreli P, Parikh N, et al. APROMISE: A novel automated PROMISE platform to standardize evaluation of tumor burden in 18F-DCFPyL images of veterans with prostate cancer. J Nucl Med. 2022;63:233\u20139.","journal-title":"J Nucl Med"},{"key":"2086_CR7","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1038\/s41598-024-53683-z","volume":"14","author":"AM Garc\u00eda Vicente","year":"2024","unstructured":"Garc\u00eda Vicente AM, Lucas Lucas C, P\u00e9rez-Beteta J, Borrelli P, Garc\u00eda Zoghby L, Amo-Salas M, et al. Analytical performance validation of aPROMISE platform for prostate tumor burden, index and dominant tumor assessment with 18F-DCFPyL PET\/CT. a pilot study. Sci Rep. 2024;14:3001.","journal-title":"Sci Rep"},{"key":"2086_CR8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, et al. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol. 2023;83:405\u201312.","journal-title":"Eur Urol"},{"key":"2086_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1053\/j.semnuclmed.2023.06.001","volume":"54","author":"S Lindgren Belal","year":"2024","unstructured":"Lindgren Belal S, Frantz S, Minarik D, Enqvist O, Wikstr\u00f6m E, Edenbrandt L, et al. Applications of artificial intelligence in PSMA PET\/CT for prostate cancer imaging. Semin Nucl Med. 2024;54:141\u20139.","journal-title":"Semin Nucl Med"},{"key":"2086_CR10","doi-asserted-by":"crossref","unstructured":"Liu J, Cundy TP, Woon DTS, Lawrentschuk N. A systematic review on artificial intelligence evaluating metastatic prostatic cancer and lymph nodes on PSMA PET scans. Cancers (Basel) [Internet]. 2024;16. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10854940\/","DOI":"10.3390\/cancers16030486"},{"key":"2086_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40644-019-0220-x","volume":"19","author":"J Damjanovic","year":"2019","unstructured":"Damjanovic J, Janssen J-C, Prasad V, Diederichs G, Walter T, Brenner W, et al. 68Ga-PSMA-PET\/CT for the evaluation of liver metastases in patients with prostate cancer. Cancer Imaging. 2019;19:37.","journal-title":"Cancer Imaging"},{"key":"2086_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40644-016-0072-6","volume":"16","author":"I Rauscher","year":"2016","unstructured":"Rauscher I, Maurer T, Fendler WP, Sommer WH, Schwaiger M, Eiber M. (68)Ga-PSMA ligand PET\/CT in patients with prostate cancer: how we review and report. Cancer Imaging. 2016;16:14.","journal-title":"Cancer Imaging"},{"key":"2086_CR13","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678\u201388.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2086_CR14","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","volume":"23","author":"JP Buteau","year":"2022","unstructured":"Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022;23:1389\u201397.","journal-title":"Lancet Oncol"},{"key":"2086_CR15","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","volume":"22","author":"A Gafita","year":"2021","unstructured":"Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M, et al. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021;22:1115\u201325.","journal-title":"Lancet Oncol"},{"key":"2086_CR16","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41391-023-00755-2","volume":"27","author":"S Huang","year":"2024","unstructured":"Huang S, Ong S, McKenzie D, Mirabelli A, Chen DC, Chengodu T, et al. Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET\/CT imaging of prostate cancer-a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2024;27:654\u201364.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2086_CR17","doi-asserted-by":"publisher","first-page":"e233460","DOI":"10.1148\/radiol.233460","volume":"312","author":"PH Kuo","year":"2024","unstructured":"Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, et al. Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION trial). Radiology. 2024;312:e233460.","journal-title":"Radiology"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02086-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-025-02086-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02086-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T13:30:42Z","timestamp":1761571842000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-025-02086-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2086"],"URL":"https:\/\/doi.org\/10.1007\/s12149-025-02086-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6360294\/v1","asserted-by":"object"}]},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients signed an informed consent agreeing to share their own anonymous information for future studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Data collection adhere to the principles of the Declaration of Helsinki. This study was approved by The Jikei University Institutional Review Board (36\u2013003(12102)).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and\/or animals participants"}}]}}